Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Leucinosis: study of a case].

M V Moura-Ribeiro, C A Funayama

    Arquivos De Neuro-Psiquiatria
    |December 1, 1985
    PubMed
    Summary

    Maple syrup urine disease (MSUD) is a rare metabolic disorder diagnosed in a neonate at 26 days. Early diagnosis and treatment with MSUD therapy led to patient improvement.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pediatric pain: prevalence, assessment, and management in a teaching hospital.

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas·2012
    Same author

    Detection of spinal muscular atrophy carriers in a sample of the Brazilian population.

    Neuroepidemiology·2011
    Same author

    Focusing on dissociated motor development in Brazilian children.

    Arquivos de neuro-psiquiatria·2001
    Same author

    Epileptic manifestations induced by midazolam in the neonatal period.

    Arquivos de neuro-psiquiatria·2001
    Same author

    Hemiparetic cerebral palsy: etiological risk factors and neuroimaging.

    Arquivos de neuro-psiquiatria·2001
    Same author

    [Medical residence in pediatric neurology in Brazil].

    Arquivos de neuro-psiquiatria·2000

    Area of Science:

    • Biochemistry
    • Genetics
    • Neonatal Medicine

    Background:

    • Maple syrup urine disease (MSUD) is an autosomal recessive metabolic disorder.
    • It is characterized by a deficiency in the branched-chain alpha-keto acid dehydrogenase complex.
    • This leads to the accumulation of branched-chain amino acids (BCAAs) and their toxic metabolites.

    Observation:

    • A female neonate presented with neurological symptoms including alternating hypertonicity and hypotonicity.
    • Additional symptoms included seizures, lethargy, poor feeding, and respiratory arrest.
    • Diagnosis was confirmed on the 26th day of life.

    Findings:

    • Elevated plasma concentrations of branched-chain amino acids (BCAAs) were identified.
    • This elevation is a key diagnostic marker for MSUD.
    • Therapeutic intervention for MSUD resulted in clinical improvement.

    Implications:

    • Early diagnosis and management of MSUD are crucial for preventing severe neurological damage.
    • Biochemical screening for elevated BCAAs is vital in neonates with suggestive symptoms.
    • Prompt treatment can significantly improve patient outcomes in MSUD cases.

    Related Experiment Videos